USPTO serial 79284012
TRB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 2, 2021
- Examiner
- LAM, HAI-LY HUYNH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with TRB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew M. Smith
Andrew M. Smith Resonate IP, LLCP.O. Box 1650Bend, OR 97709UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceuticals, namely, anti-neurodegenerative, anti-neurotrophic, anti-antineurotoxic, neuroprotective and neurorestorative effect agents; pharmaceuticals, namely, immunopharmaceuticals; medical and veterinary preparations, namely, preparations for use in treating joint disease in horses, and antioxidants; pharmaceutical and medicinal preparations and substances for treating and preventing ophthalmic, ocular, neurological, metabolic, dermatological, arthritic, cognitive, or sexual dysfunction-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for treating and preventing joint, ligament, tendon, cartilage, bone, damaged skin or tissue-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for the treatment of central or peripheral nervous system-related, spinal cord-related, or early stages of traumatic or acute vascular injury-related disorders and diseases; pharmaceutical and medicinal preparations and substances for the treatment of pain, inflammation, physical lesions, and wounds; analgesics; anti-inflammatories; medicines for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; medicines for use as surgical aid during cataract surgery procedures; medicines for the treatment of osteoarthritis and rheumatoid arthritis; medicines for the prevention of osteoporosis; medicines for the treatment of musculo-skeletal conditions, disorders or diseases; medicines for the treatment of tendinopathy; medicines for joint recovery after arthroscopy; medicines to help assist with the regeneration of ligament and tendon fibers; medicines for the treatment of immune system related diseases and disorders; medicines for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; pharmaceutical drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; pharmaceutical drugs for use as surgical aid during cataract surgery procedures; pharmaceutical drugs for the treatment of osteoarthritis and rheumatoid arthritis; pharmaceutical drugs for the prevention of osteoporosis; pharmaceutical drugs for the treatment of musculo-skeletal conditions, disorders or diseases; pharmaceutical drugs for the treatment of tendinopathy; pharmaceutical drugs for joint recovery after arthroscopy; pharmaceutical drugs to help assist with the regeneration of ligament and tendon fibers; pharmaceutical drugs for the treatment of immune system related diseases and disorders; pharmaceutical drugs for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; therapeutic drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic drugs for use as surgical aid during cataract surgery procedures; therapeutic drugs for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic drugs for the prevention of osteoporosis; therapeutic drugs for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic drugs for the treatment of tendinopathy; therapeutic drugs for joint recovery after arthroscopy; therapeutic drugs to help assist with the regeneration of ligament and tendon fibers; therapeutic drugs for the treatment of immune system related diseases and disorders, and therapeutic agents for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic agents for use as surgical aid during cataract surgery procedures; therapeutic agents for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic agents for the prevention of osteoporosis; therapeutic agents for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic agents for the treatment of tendinopathy; therapeutic agents for joint recovery after arthroscopy; therapeutic agents to help assist with the regeneration of ligament and tendon fibers; therapeutic agents for the treatment of immune system related diseases and disorders; transdermal patches featuring vitamins for increasing energy for medical use; biological cartilage, bone or skin tissue intended for subsequent implantation; biological preparations for medical or veterinary use, namely, for the treatment of infectious diseases; sanitary preparations for medical purposes; dietetic food and substances in the nature of food supplements and vitamins supplements all adapted for medical or veterinary use; food for babies; dietary supplements for humans and animals; meal replacements, namely, meal replacement bars adapted for medical use and meal replacement beverages adapted for medical use, and dietetic beverages adapted for medical and veterinary use; materials for dressings, namely, dressings for wounds, burns or surgery, adhesive bandages, gauze for dressings, pledgets; disinfectants | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TRB CHEMEDICA INTERNATIONAL SA
- Other trademarks owned by TRB CHEMEDICA INTERNATIONAL SA
- Other trademarks owned by TRB CHEMEDICA INTERNATIONAL SA
- Other trademarks in Class 005
- Similar marks named TRB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 2, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 26, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 26, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 18, 2024 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Jun 30, 2024 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jun 9, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 26, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 26, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 26, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 30, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 18, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 18, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 18, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 5, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 5, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 2, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 2, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 17, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 17, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 28, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 13, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 8, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 18, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 30, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 30, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 29, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 28, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 21, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| May 1, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 27, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |